Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
  • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D267/02—Seven-membered rings
  • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
  • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• This invention relates to substituted benzamide derivatives having a gastrointestinal motility enhancing activity, processes for the preparation thereof, and a method of using the same, and pharmaceutical compositions containing said compound as an active ingredient.
• the present inventors have extensively studied in order to obtain novel substituted benzamide derivatives having excellent gastrointestinal motility enhancing activity and have found that certain substituted benzamide derivatives wherein the nitrogen atom in the amide moiety is bound to the carbon atom at the 2-position of a morpholine or hexahydro-1,4-oxazepine group via an alkylene group show the desired activity and further that some of these substituted benzamide derivatives show more potent gastrointestinal motility enhancing activity but show less adverse effects on the central nervous system than metoclopramide.
• An object of the invention is to provide novel substituted benzamide derivatives having excellent gastrointestinal motility enhancing activity. Another object of the invention is to provide processes for the preparation of the compounds. A further object of the invention is to provide a pharmaceutical composition containing as an active ingredient the compounds as set forth above which are useful as a gastrointestinal motility enhancing agent.
• the substituted benzamide derivatives of this invention are compounds of the formula: wherein R is hydrogen, a C2-C5 alkoxycarbonyl, benzyloxycarbonyl, a heteroaryl(C1-C3)alkyl in which the heteroaryl is furyl, thienyl, pyridyl, or 1,2-benzisoxazolyl, a phenyl(C3-C5)alkenyl, or -T-(Y) p -R6 (wherein T is a single bond or a C1-C6 alkylene, Y is oxygen, sulfur or carbonyl, R6 is phenyl, a phenyl substituted by one to five members each independently selected from the group consisting of a halogen, a C1-C4 alkyl, trifluoromethyl, a C1-C4 alkoxy, nitro, cyano and amino, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T
• the pharmaceutically acceptable acid addition salts of the compounds (I) include, for example, inorganic acid addition salts (e.g. hydrochloride, hydrobromide, hydroiodide, sulfate and phosphate) and organic acid addition salts (e.g. oxalate, maleate, fumarate, lactate, malate, citrate, tartrate, benzoate and methanesulfonate).
• inorganic acid addition salts e.g. hydrochloride, hydrobromide, hydroiodide, sulfate and phosphate
• organic acid addition salts e.g. oxalate, maleate, fumarate, lactate, malate, citrate, tartrate, benzoate and methanesulfonate.
• the pharmaceutically acceptable quaternary ammonium salts of the compounds (I) mean pharmaceutically acceptable ammonium salts of the compounds of the formula (I) wherein R is other than hydrogen, alkoxycarbonyl or benzyloxycarbonyl and include, for example, quaternary ammonium salts with lower alkyl halogenides (e.g. methyl iodide, methyl bromide, ethyl iodide and ethyl bromide), lower alkyl lower alkylsulfonates (e.g. methyl methanesulfonate and ethyl methanesulfonate) and lower alkyl arylsulfonates (e.g. methyl p-toluenesulfonate.
• lower alkyl halogenides e.g. methyl iodide, methyl bromide, ethyl iodide and ethyl bromide
• N-oxide derivatives of the compounds (I) mean N-oxide derivatives of the compounds of the formula (I) wherein R is other than hydrogen, alkoxycarbonyl, benzyloxycarbonyl, thienylalkyl, pyridylalkyl, or -T'-S-R6 (R6 is as defined above and T' is an alkylene), and R1 is other than alkylthio.
• the compounds (I), acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof may optionally be present in the form of a hydrate or solvate, and the hydrate and solvate are also included in this invention.
• the compounds of the formula (I) contain one or more asymmetric carbon atoms, and hence, they may be present in the form of various stereoisomers. This invention includes also these stereoisomers and a mixture thereof and racemic compounds.
• alkyl group, alkyl moiety, alkylene group, or alkylene moiety includes straight or branched chain groups.
• alkoxycarbonyl includes, for example, methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl.
• alkylene includes, for example, methylene, ethylene, methylmethylene, trimethylene, propylene, dimethylmethylene, tetramethylene, pentamethylene and hexamethylene.
• halogen includes fluorine, chlorine, bromine, and iodine, preferably fluorine, chlorine, and bromine.
• alkyl includes, for example, methyl, ethyl, propyl, isopropyl, butyl, pentyl and hexyl.
• alkoxy includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, isopentyloxy, hexyloxy, isohexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy, undecyloxy and dodecyloxy.
• cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• alkenyloxy means a group which has one double bond at the position other than the carbon atom adjacent to the oxygen atom, and includes, for example, allyloxy, 2-butenyloxy, 3-butenyloxy, 3-methyl-2-butenyloxy, 3- or 4-pentenyloxy, 4- or 5-hexenyloxy and 6-heptenyloxy.
• alkynyloxy means a group which has one triple bond at the position other than the carbon atom adjacent to the oxygen atom, and includes, for example, 2-propynyloxy, 3-butynyloxy and 5-hexynyloxy.
• the "alkoxy interrupted by one or two oxygens or carbonyls” includes, for example, 2-methoxyethoxy, (2-methoxyethoxy)methoxy, 2,2-dimethoxyethoxy, 2-oxopropoxy and 3-oxobutoxy.
• alkanoylamino includes, for example, acetylamino, propionylamino, butyrylamino and isobutyrylamino.
• R is pyridylmethyl, (wherein Y and p are as defined above, R7 is hydrogen, fluorine, chlorine, trifluoromethyl, cyano, or nitro, and q is an integer of 1 to 4), pentafluorobenzyl, 2-nitro-4-chlorobenzyl, 1-phenylethyl, or naphthylmethyl;
• R1 is hydroxy, a C1-C10 alkoxy, a C5-C6 cycloalkyloxy, a C3-C5 alkenyloxy, a C3-C5 alkynyloxy, a C2-C4 alkoxy interrupted by one carbonyl, a C2-C5 alkoxy in which the carbon atom at any position other than the 1-position is substituted by one hydroxy, or a substituted C1-C5 alkoxy in which the substituent is a halogen, cyano, a C2-
• More preferred compounds are compounds of the formula: wherein R a is pyridylmethyl, benzyl, fluorobenzyl, chlorobenzyl, trifluoromethylbenzyl, cyanobenzyl, or 3-(4-chlorophenoxy)propyl, R 1a is a C1-C7 alkoxy, cyclopentyloxy, 3-butenyloxy, 3-methyl-2-butenyloxy, 2-oxopropoxy, 2-hydroxypropoxy, or 2-chloroethoxy, R3' is amino, dimethylamino or a C2-C3 alkanoylamino, R5' is hydrogen or methyl, and n is 1 or 2, and pharmaceutically acceptable acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof.
• Particularly preferred compounds are compounds of the formula: wherein R b is pyridylmethyl, benzyl, fluorobenzyl, chlorobenzyl, or 3-(4-chlorophenoxy)propyl, and R 1b is methoxy, ethoxy, butoxy, isobutoxy, pentyloxy, isopentyloxy, 3-methyl-2-butenyloxy, or 2-hydroxypropoxy, and pharmaceutically acceptable acid addition salts and N-oxide derivatives thereof.
• the particularly preferred compounds are the following compounds and pharmaceutically acceptable acid addition salts thereof: 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide, 4-amino-5-chloro-2-ethoxy-N-[[4-(3-pyridyl)methyl-2-morpholinyl]methyl]benzamide, 4-amino-N-[(4-benzyl-2-morpholinyl)methyl]-5-chloro-2-(3-methyl-2-butenyloxy)benzamide, 4-amino-N-[(4-benzyl-2-morpholinyl)methyl]-2-butoxy-5-chlorobenzamide, 4-amino-2-butoxy-5-chloro-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide, 4-amino-N-[(4-benzyl-2-morpholinyl)methyl]-5-chloro
• the compounds of this invention can be prepared by various processes, for example, by the following processes.
• the compounds of the formula (I) can be prepared by reacting a compound of the formula: wherein R1, R2, R3 and R4 are as defined above, or a reactive derivative thereof with a compound of the formula: wherein R5, X, m and n are as defined above, and R' is the same as R except hydrogen, and when a compound of the formula (I) wherein R is a C2-C5 alkoxycarbonyl, benzyloxycarbonyl or benzyl is obtained, optionally removing the said group from the product.
• the reactive derivative of the compound (II) includes, for example, activated esters, acid anhydrides, acid halides (particularly acid chloride) and lower alkyl esters.
• activated esters are p-nitrophenyl ester, 2,4,5-trichlorophenyl ester, pentachlorophenyl ester, cyanomethyl ester, N-hydroxysuccinimide ester, N-hydroxyphthalimide ester, 1-hydroxybenzotriazole ester, N-hydroxy-5-norbornene-2,3-dicarboximide ester, N-hydroxypiperidine ester, 8-hydroxyquinoline ester, 2-hydroxyphenyl ester, 2-hydroxy-4,5-dichlorophenyl ester, 2-hydroxypyridine ester and 2-pyridylthiol ester.
• the acid anhydrides include symmetric acid anhydrides and mixed acid anhydrides.
• Suitable examples of the mixed acid anhydrides are mixed acid anhydrides with alkyl chloroformates (e.g. ethyl chloroformate and isobutyl chloroformate), mixed acid anhydrides with aralkyl chloroformates (e.g. benzyl chloroformate), mixed acid anhydrides with aryl chloroformates (e.g. phenyl chloroformate) and mixed acid anhydrides with alkanoic acids (e.g. isovaleric acid and pivalic acid).
• alkyl chloroformates e.g. ethyl chloroformate and isobutyl chloroformate
• aralkyl chloroformates e.g. benzyl chloroformate
• mixed acid anhydrides with aryl chloroformates e.g. phenyl chloroformate
• alkanoic acids e
• the reaction can be carried out in the presence of a condensation agent, such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N'-carbonyldiimidazole and 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
• a condensation agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N'-carbonyldiimidazole and 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
• condensation agent When dicyclohexylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride is used as the condensation agent, such reagents as N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, or N-hydroxy-5-norbornene-2,3-dicarboximide may be added to the reaction system.
• reagents as N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, or N-hydroxy-5-norbornene-2,3-dicarboximide may be added to the reaction system.
• Suitable solvent is selected in accordance with the kinds of the starting compounds, and includes, for example, aromatic hydrocarbons (e.g. benzene, toluene and xylene), ethers (e.g. diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane), halogenated hydrocarbons (e.g. dichloromethane and chloroform), ethyl acetate, acetonitrile, dimethylformamide, dimethyl sulfoxide, ethylene glycol and water.
• aromatic hydrocarbons e.g. benzene, toluene and xylene
• ethers e.g. diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane
• halogenated hydrocarbons e.g. dichloromethane and chloroform
• ethyl acetate acetonitrile
• the reaction may optionally be carried out in the presence of a base.
• a base Suitable examples of the base are alkali metal bicarbonates (e.g. sodium bicarbonate and potassium bicarbonate), alkali metal carbonates (e.g. sodium carbonate and potassium carbonate), and organic bases (e.g. triethylamine, tributylamine, diisopropylethylamine and N-methylmorpholine).
• the compound (III) may be used in an excess amount to serve as the base.
• the reaction temperature may vary in accordance with the kinds of the starting compounds, but is usually in the range of from about -30°C to about 200°C, preferably from about -10°C to about 150°C, and the reaction period of time is usually in the range of from 1 hour to 48 hours.
• the compound (II) has such a functional group which interferes with the reaction as an aliphatic amino, it is preferable to block previously the group with an appropriate protecting group such as a lower alkanoyl (e.g. acetyl).
• an appropriate protecting group such as a lower alkanoyl (e.g. acetyl).
• the protecting group can be removed after the reaction.
• the base includes, for example, alkali metal hydroxides (e.g. sodium hydroxide and potassium hydroxide).
• the hydrolysis is usually carried out at a temperature of from about 50°C to about 100°C for 0.5 to 24 hours.
• the hydrogenolysis can be carried out in an appropriate solvent in the presence of a catalyst.
• the solvent includes, for example, alcohols (e.g. methanol, ethanol and isopropyl alcohol), ethyl acetate, acetic acid, dioxane, water, or a mixture thereof.
• the catalyst includes, for example, palladium on carbon. The hydrogenolysis is usually carried out at a temperature of from 20°C to about 80°C for 1 to 24 hours.
• the product may further be subjected to hydrolysis under an acidic or alkaline condition to give a compound of the formula (I) wherein R3 is amino.
• the alkanoyl group can easily be removed. For instance, when a lower alkyl ester of compound (II) wherein R3 is an alkanoylamino is reacted with a compound (III) at 120 - 150°C, there can be obtained a compound of the formula (I) wherein R3 is amino.
• the starting compounds (III) are novel and can be prepared, for example, by the methods as disclosed in Reference Examples 1, 3 to 6, 56, 58, 60 to 76, and 79 hereinafter.
• the compounds of the formula: wherein R b is as defined above, and R 1c is methoxy, ethoxy, butoxy, isobutoxy, pentyloxy, or isopentyloxy, can be prepared by chlorinating a compound of the formula: wherein R b and R 1c are as defined above, and R3'' is a C2-C5 alkanoylamino, followed by removing the alkanoyl group from the product.
• the first chlorination step can be carried out by a known method, for example, by reacting the compound (IV) with a chlorinating agent in an appropriate solvent.
• the chlorinating agent includes, for example, N-chlorosuccinimide, iodobenzene dichloride and t-butyl hypochlorite.
• the solvent may vary depending for example on the kinds of the chlorinating agent, and includes, for example, halogenated hydrocarbons (e.g. dichloromethane, chloroform and 1,2-dichloroethane), ethers (e.g. tetrahydrofuran), acetonitrile, dimethylformamide and pyridine.
• the reaction temperature may vary depending for example on the kinds of the chlorinating agent, but is usually in the range of from about -20°C to about 100°C, and the reaction period of time is usually in the range of from 1 hour to 24 hours.
• the removal of the alkanoyl group from the chlorinated product is effected by hydrolysis or by treatment with an organic amine.
• the hydrolysis is carried out in an appropriate solvent under an acidic or alkaline condition.
• the solvent includes, for example, alcohols (e.g. methanol, ethanol and isopropyl alcohol), dioxane, water, or a mixture thereof.
• the acid includes mineral acids (e.g. hydrochloric acid)
• the base includes alkali metal hydroxides (e.g. sodium hydroxide and potassium hydroxide) and alkali metal carbonates (e.g. sodium carbonate and potassium carbonate).
• the treatment of the chlorinated product with an organic amine is carried out in the absence or presence of a solvent.
• the solvent includes, for example, aromatic hydrocarbons (e.g. benzene and toluene), ethers (e.g. tetrahydrofuran and dioxane), halogenated hydrocarbons (e.g. dichloromethane and chloroform), alcohols (e.g. methanol, ethanol and isopropyl alcohol), ethyl acetate and acetonitrile.
• aromatic hydrocarbons e.g. benzene and toluene
• ethers e.g. tetrahydrofuran and dioxane
• halogenated hydrocarbons e.g. dichloromethane and chloroform
• alcohols e.g. methanol, ethanol and isopropyl alcohol
• ethyl acetate and acetonitrile e.g. acetonitrile.
• the organic amine includes, for example, lower alkylamines (e.g. methylamine and
• the starting compound (IV) can be prepared, for example, by reacting an appropriate 4-alkanoylamino-2-alkoxybenzoic acid or a reactive derivative thereof with an appropriate 2-aminomethyl-4-substituted morpholine in the same manner as in the above process (a).
• the compound (Ic) can also be prepared by reducing a compound of the formula: wherein R b and R 1c are as defined above.
• the above reduction can be carried out by a conventional process, for example, by treating the compound (V) with a reducing agent in an appropriate solvent.
• the reducing agent includes a combination of a metal (e.g. tin, zinc or iron) or a metal salt (e.g. stannous chloride) and an acid (e.g. hydrochloric acid or acetic acid).
• Stannous chloride may be used alone as the reducing agent.
• the reduction can also be carried out by hydrogenating the compound (V) in the presence of a catalyst in a solvent.
• a suitable example of the catalyst is palladium on carbon.
• a suitable solvent is selected in accordance with the kinds of the reducing agent or means, and includes, for example, alcohols (e.g. methanol, ethanol and isopropyl alcohol), ethyl acetate, acetic acid, dioxane and water, or a mixture thereof.
• the reaction temperature may vary depending on the kinds of the reducing agent or means, but is usually in the range of from about 10°C to about 100°C, and for catalytic hydrogenation, preferably from about 10°C to about 50°C.
• the reaction period of time is usually in the range of from 1 hour to 24 hours.
• the starting compound (V) can be prepared, for example, by reacting an appropriate 2-alkoxy-5-chloro-4-nitrobenzoic acid or a reactive derivative thereof with an appropriate 2-aminomethyl-4-substituted morpholine in the same manner as in the above process (a).
• the 2-alkoxy-5-chloro-4-nitrobenzoic acid can be prepared, for example, by the process as disclosed in G.B. Patent No. 1,153,796.
• the compound (Ic) can also be prepared by reacting a compound of the formula: wherein R b is as defined above, with a compound of the formula: Z-R8 (VII) wherein R8 is methyl, ethyl, butyl, isobutyl, pentyl, or isopentyl, and Z is a residue of a reactive ester of an alcohol.
• the residue of reactive ester of an alcohol as defined for Z includes, for example, a halogen atom (e.g. chlorine, bromine or iodine), a lower alkylsulfonyloxy (e.g. methanesulfonyloxy or ethanesulfonyloxy), an arylsulfonyloxy (e.g. benzenesulfonyloxy, p-toluenesulfonyloxy or m-nitrobenzenesulfonyloxy) and a lower alkoxysulfonyloxy (e.g. methoxysulfonyloxy or ethoxysulfonyloxy).
• a halogen atom e.g. chlorine, bromine or iodine
• a lower alkylsulfonyloxy e.g. methanesulfonyloxy or ethanesulfonyloxy
• the above reaction is usually carried out in an appropriate solvent in the presence of a base.
• a base Suitable examples of the base are alkali metal carbonates (e.g. sodium carbonate and potassium carbonate), quaternary ammonium hydroxides (e.g. tetrabutylammonium hydroxide and benzyltriethylammonium hydroxide), alkali metal alkoxides (e.g. sodium methoxide and sodium ethoxide) and alkali metal hydrides (e.g. sodium hydride and potassium hydride).
• alkali metal carbonates e.g. sodium carbonate and potassium carbonate
• quaternary ammonium hydroxides e.g. tetrabutylammonium hydroxide and benzyltriethylammonium hydroxide
• alkali metal alkoxides e.g. sodium methoxide and sodium ethoxide
• alkali metal hydrides e.g. sodium
• a suitable solvent may be selected in accordance with the kinds of the starting compound or base and includes, for example, dichloromethane, acetone, acetonitrile, methanol, ethanol, isopropyl alcohol, diglyme, dimethylformamide and dimethylacetamide.
• an alkali metal iodide e.g. sodium iodide or potassium iodide
• the above reaction can also be carried out in the presence of a strong base (e.g. sodium hydroxide or potassium hydroxide) and a phase transfer catalyst in a phase transfer solvent system such as dichloromethane-water.
• a strong base e.g. sodium hydroxide or potassium hydroxide
• a phase transfer catalyst in a phase transfer solvent system such as dichloromethane-water.
• Suitable examples of the phase transfer catalyst are tetrabutylammonium bromide, cetyltrimethylammonium bromide, benzyltriethylammonium chloride and tetrabutylammonium bisulfate.
• the reaction temperature may vary depending for example on the kinds of the starting compound, but is usually in the range of from about 5°C to about 150°C, and the reaction period of time is usually in the range of 5 to 48 hours.
• the starting compound (VI) can be prepared, for example, by reacting 2-acetoxy-4-acetylamino-5-chlorobenzoic acid or a reactive derivative thereof with an appropriate 2-aminomethyl-4-substituted morpholine in the same manner as in the above process (a), followed by hydrolysis of the resulting product.
• the compound (VI) can also be prepared by demethylating the corresponding 2-methoxy compound with sodium ethanethiolate in dimethylformamide or with boron tribromide in dichloromethane.
• the compounds (I) prepared by the above processes can be isolated and purified by conventional techniques, such as chromatography, recrystallization or reprecipitation.
• the compounds (I) may be obtained in the form of a free base, acid addition salt, hydrate or solvate depending on the kinds of the starting compounds, the reaction and treating conditions.
• the acid addition salt can be converted into a free base by treating it with a base such as an alkali metal hydroxide or an alkali metal carbonate in the usual manner.
• the free base may be converted into an acid addition salt by treating it with various acids in the usual manner. For example, when a compound of the formula (I) is reacted with an appropriate acid in a solvent and the reaction product is purified by recrystallization or reprecipitation, there is obtained an acid addition salt of the compound (I).
• the solvent includes, for example, chloroform, acetone, methanol, ethanol, isopropyl alcohol and water, or a mixture thereof.
• the reaction temperature is usually in the range of from about 0°C to about 80°C, and the reaction period of time is usually in the range of from 30 minutes to 48 hours.
• the compounds of the formula (I) in which R is other than hydrogen, alkoxycarbonyl or benzyloxycarbonyl may be converted into their quaternary ammonium salts in the usual manner.
• the quaternization is carried out by reacting the compound (I) with an appropriate quaternizing agent in the absence or presence of a solvent.
• the solvent includes, for example, aromatic hydrocarbons (e.g. benzene and toluene, xylene), ketones (e.g. acetone, methyl ethyl ketone and methyl isobutyl ketone) and acetonitrile, or a mixture thereof.
• the reaction temperature may vary depending on the kinds of the compound (I) and the quaternizing agent, but is usually in the range of about 10°C to 130°C, and the reaction period of time is usually in the range of 1 to 72 hours.
• the compounds of the formula (I) in which R is other than hydrogen, alkoxycarbonyl, benzyloxycarbonyl, thienylalkyl, pyridylalkyl, or -T'-S-R6 wherein R6 and T' are as defined above may be converted into their N-oxide derivatives in the usual manner.
• the N-oxidation is carried out by reacting the compound (I) with an appropriate oxidizing agent in a solvent.
• the oxidizing agent includes, for example, hydrogen peroxide and organic peracids (e.g. peracetic acid, perbenzoic acid, m-chloroperbenzoic acid and perphthalic acid).
• a suitable solvent is selected in accordance with the kinds of the oxidizing agent, and includes, for example, water, acetic acid, alcohols (e.g. methanol and ethanol), ketones (e.g. acetone), ethers (e.g. diethyl ether and dioxane) and halogenated hydrocarbons (e.g. dichloromethane and chloroform).
• the reaction temperature may vary depending on the kinds of the oxidizing agent, but is usually in the range of 0°C to 100°C, and the reaction period of time is usually in the range of 1 to 72 hours.
• Test 1 Gastric emptying enhancing activity
• test meal phenol red 0.05 % in a 1.5 % aqueous methylcellulose solution
• test compounds dissolved or suspended in a 0.5 % tragacanth solution, were orally administered 60 minutes before administration of the test meal.
• the rate of gastric emptying was calculated according to the amount of phenol red remaining in the stomach, and the activity of the test compounds was expressed in terms of increase in the emptying rate from the control.
• the number of animals used was 5 for the control and each dose of metoclopramide hydrochloride monohydrate and 4 for each dose of the other test compounds. The results are shown in Table 1.
• the compounds of this invention exhibited potent gastric emptying enhancing activity at a dose of 2.0 mg/kg or less. The effect was stronger than that of metoclopramide hydrochloride monohydrate. On the other hand, Compound B did not show any effect even at a dose of 10.0 mg/kg.
• mice Male ddY mice, weighing 18 - 25 g, were used in groups of 10 animals each.
• mice Male ddY mice, weighing 18 - 25 g, were used in groups of 3 animals each. According to the method of Irwin [cf. Psychopharmacologia, 13 , 222-257 (1968)], comprehensive observation of behavioral and physiologic states was carried out for 2 hours after the oral treatment with 100 mg/kg of the test compound, dissolved or suspended in a 0.5 % tragacanth solution. Liability of the test compounds to the central nervous system effect was expressed with the following marks, according to the total sum of potencies for the individually analyzed effects, such as catalepsy, ptosis or hypolocomotion.
• the compounds of the formula (I) and pharmaceutically acceptable acid addition salts, quaternary ammonium salts, or N-oxide derivatives thereof have excellent gastrointestinal motility enhancing activity with less toxicity, and hence, are useful as a gastrointestinal motility enhancing agent. They can be used in the prophylaxis and treatment of disorders associated with gastrointestinal motor impairment in mammals including human being, such as dyspepsia, esophageal reflux, gastric stasis, anorexia, nausea, vomiting, and abdominal discomfort which are seen in acute and chronic gastritis, gastric and duodenal ulcers, gastrio neurosis and gastroptosis.
• They can also be used in the prophylaxis and treatment of esophageal and biliary duct disorders and constipation. Further, they can be used in the prophylaxis and treatment of nausea and vomiting associated with emetogenic cancer chemotherapeutic agents such as cisplatin.
• the compounds of the formula (I) and pharmaceutically acceptable acid addition salts, quaternary ammonium salts, or N-oxide derivatives thereof can be administered by oral, parenteral or intrarectal route.
• the clinical dose of the compounds (I) and pharmaceutically acceptable salts or N-oxide derivatives thereof may vary according to the kinds of the compounds, adminstration routes, severity of disease and age of patients, but is usually in the range of 0.001 to 20 mg per kg of body weight per day, preferably 0.004 to 5 mg per kg of body weight per day, in human.
• the dose may be divided and administered in two or several times per day.
• the compounds of the formula (I) and pharmaceutically acceptable salts or N-oxide derivatives thereof are usually administered to patients in the form of a pharmaceutical composition which contains a non-toxic and effective amount of the compounds.
• the pharmaceutical composition is usually prepared by admixing the active compounds (I), their salts or N-oxide derivatives with conventional pharmaceutical carrier materials which are unreactive with the active compounds (I), their salts or N-oxide derivatives.
• Suitable examples of the carrier materials are lactose, glucose, mannitol, dextrin, cyclodextrin, starch, sucrose, magnesium aluminosilicate tetrahydrate, synthetic aluminum silicate, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropylstarch, calcium carboxymethylcellulose, ion exchange resin, methylcellulose, gelatin, acacia, pullulan, hydroxypropylcellulose, low substituted hydroxypropylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, veegum, carboxyvinyl polymer, titanium dioxide, sorbitan fatty acid ester, sodium lauryl sulfate, cacao butter, glycerin, glycerides of saturated fatty acids, anhydrous lanolin, glycerogelatin, polysorbate,
• the pharmaceutical composition may be in the dosage form of tablets, capsules, granules, fine granules, powders, syrups, suspension, suppositories or injections. These preparations may be prepared by conventional methods. Liquid preparations may be prepared by dissolving or suspending the active compounds in water or other suitable vehicles, when used. Tablets, granules and fine granules may be coated in a conventional manner.
• the pharmaceutical composition may contain as the active ingredient the compound of the formula (I), its pharmaceutically acceptable salt or N-oxide derivative in the ratio of 0.5 % by weight or more, preferably 1 to 70 % by weight, based upon the whole weight of the composition.
• the composition may further contain one or more other therapeutically active compounds.
• the reaction mixture is stirred at 25°C overnight and then washed successively with water, 1N aqueous sodium hydroxide solution and saturated aqueous sodium chloride solution, and dried over magnesium sulfate.
• the solvent is distilled off under reduced pressure to give the title compound (4.0 g).
• the free base thus obtained is treated with fumaric acid in hot isopropyl alcohol.
• the precipitate is collected and recrystallized from isopropyl alcohol to give the 3/4 fumarate of the title compound, mp 161-163°C.
• Example 1(1) The title compound is prepared in substantially the same manner as in Example 1(1), using 2-(2-aminoethyl)-4-benzylmorpholine in place of 2-aminomethyl-4-(4-fluorobenzyl)morpholine in Example 1(1), mp 149-151°C (recrystallized from methanol).
• Example 6(1) The title compound is prepared in substantially the same manner as in Example 6(1), using 2-(2-aminoethyl)-4-benzylmorpholine in place of 2-aminomethyl-4-(4-cyanobenzyl)morpholine in Example 6(1).
• the free base thus obtained is treated in substantially the same manner as in Example 6(2) to give the hemifumarate 3/2 EtOH, mp 68-72°C (recrystallized from ethanol-diethyl ether).
• the 1/4 hydrate of the title compound is prepared in substantially the same manner as in Example 6(1), using 2-(2-aminoethyl)-4-(4-cyanobenzyl)morpholine in place of 2-aminomethyl-4-(4-cyanobenzyl)morpholine in Example 6(1), mp 180-182°C (recrystallized from isopropyl alcohol).
• the title compound is prepared in substantially the same manner as in Example 6(1), using 2-aminomethyl-4-benzylmorpholine and 2,3-methylenedioxybenzoic acid, respectively, in place of 2-aminomethyl-4-(4-cyanobenzyl)morpholine and 4-amino-5-chloro-2-methoxybenzoic acid in Example 6(1).
• the free base thus obtained is treated in substantially the same manner as in Example 6(2) to give the fumarate 1/4 hydrate of the title compound, mp 144-146°C (recrystallized from ethanol).
• the hemihydrate of the title compound is prepared in substantially the same manner as in Example 6(1), using 2-aminomethyl-4-[3-(4-chlorophenoxy)propyl]morpholine and 5-chloro-4-dimethylamino-2-methoxybenzoic acid, respectively, in place of 2-aminomethyl-4-(4-cyanobenzyl)morpholine and 4-amino-5-chloro-2-methoxybenzoic acid in Example 6(1), mp 128-130°C (recrystallized from ethanol).
• Example 6(1) The title compound is prepared in substantially the same manner as in Example 6(1), using 5-chloro-4-dimethylamino-2-methoxybenzoic acid in place of 4-amino-5-chloro-2-methoxybenzoic acid in Example 6(1), mp 161-163°C (recrystallized from ethanol).
• Example 14(1) The title compound is prepared in substantially the same manner as in Example 14(1), using 2-aminomethyl-4-(2-chlorobenzyl)-5,5-dimethylmorpholine in place of 2-aminomethyl-4-(2-chlorobenzyl)-6-methylmorpholine in Example 14(1), mp 181-184°C (recrystallized from ethanol).
• Example 14(1) The title compound is prepared in substantially the same manner as in Example 14(1), using 2-aminomethyl-4-benzyl-hexahydro-1,4-oxazepine in place of 2-aminomethyl-4-(2-chlorobenzyl)-6-methylmorpholine in Example 14(1).
• the free base thus obtained is treated in substantially the same manner as in Example 14(2) to give the fumarate of the title compound, mp 180-183°C (recrystallized from isopropyl alcohol).
• the starting material 4-acetylamino-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide, is prepared in substantially the same manner as in Example 1(1), using 4-acetylamino-2-ethoxybenzoic acid in place of 4-amino-5-chloro-2-ethoxybenzoic acid in Example 1(1).
• the compounds of Examples 18 to 22, 45 to 47, 52, 63 to 68, 79 to 81, 83, and 88 to 95 are prepared by chlorinating the appropriate 4-acetylaminobenzamide derivatives in substantially the same manner as in Example 157 and subsequently hydrolyzing the resulting 4-acetylamino-5-chlorobenzamide derivatives, in substantially the same manner as in Example 158.
• the title compound is prepared in substantially the same manner as in Reference Example 1(1) and (2), using 2-chloromethyl-4-phenylmorpholine in place of 4-benzyl-2-chloromethylmorpholine in Reference Example 1(1).
• reaction mixture is washed successively with aqueous sodium hydroxide solution, water and saturated aqueous sodium chloride solution, and dried over magnesium sulfate.
• the solvent is distilled off under reduced pressure, and the residue is recrystallized from toluene to give the title compound (101 g), mp 110-111°C.
• 2-Acetylaminomethyl-4-benzylmorpholine 120 g is dissolved in a mixture of ethanol (1000 ml) and acetic acid (30 ml) and hydrogenated over 10% palladium on carbon (5 g) at about 60°C. After the calculated amount of the hydrogen is absorbed, the catalyst is filtered off. The filtrate is evaporated under reduced pressure to give the title compound as an oil.
• the title compounds are prepared in substantially the same manner as in Reference Example 56, using the products of Reference Examples 4, 7 to 18, 21 to 33, 38 to 41, and 53 to 55 in place of 2-acetylaminomethyl-4-(4-fluorobenzyl)morphoine in Reference Example 56.
• the title compounds are prepared in substantially the same manner as in Reference Example 58, using the products of Reference Examples 19, 20, 34 to 37, 42 to 45, 47 to 52, and 55 in place of 2-acetylaminomethyl-4-[3-(4-chlorophenoxy)propyl]morpholine in Reference Example 58.
• a solution of 4-benzyl-2-cyanomethylmorpholine (20 g) in a mixture of ethanol (160 ml) and 28% ammonia water (10 ml) is hydrogenated over Raney nickel (2 g, wet) at 25°C for 2 hours.
• the catalyst is filtered off and the filtrate is evaporated under reduced pressure.
• the residual oil (16.5 g) is treated with a solution of maleic acid in ethanol to give the maleate, which is recrystallized from ethanol-ethyl acetate to give the sesquimaleate of the title compound, mp 123-125°C.
• reaction mixture is washed successively with aqueous sodium hydroxide solution, water and saturated aqueous sodium chloride solution, and dried over magnesium sulfate. After removal of the solvent under reduced pressure, the residue is chromatographed on silica gel with ethyl acetate to give the title compound (15 g) as an oil.
• 2-(2-Chlorobenzyl)amino-2-methylpropanol is prepared in substantially the same manner as in Reference Example 72, using 2-amino-2-methylpropanol in place of 2-amino-1-methylethanol in Reference Example 72. This product is converted to the oily title compound in substantially the same manner as in Reference Examples 73 to 76.
• 3-Benzylaminopropanol is prepared in substantially the same manner as in Reference Example 72, using 3-aminopropanol and benzaldehyde, respectively, in place of 2-amino-1-methylethanol and 2-chlorobenzaldehyde in Reference Example 72.
• This product is converted to the oily title compound in substantially the same manner as in Reference Examples 73 to 76.
• the title compound is prepared in substantially the same manner as in Reference Example 81, using hexylamine in place of benzylamine in Reference Example 81, mp 161-163°C (recrystallized from diisopropyl ether-hexane).
• 2-acetylamino-4-chlorobenzoic acid (33.0 g) is nitrated to give 2-acetylamino-4-chloro-5-nitrobenzoic acid(30.0 g).
• a solution of the nitrated acid (11.3 g) and 40% aqueous dimethylamine solution (40 ml) in ethanol (100 ml) is refluxed for 5 hours and then evaporated under reduced pressure.
• To the residue is added water (100 ml), and the resulting solution is adjusted to the pH of about 4 with acetic acid.
• the precipitate is collected and recrystallized from ethanol to give the title compound (8.6 g), mp 230-255°C.
• the title compound is prepared from 2-fluoro-5-sulfamoylbenzoic acid and cyclopropylamine in substantially the same manner as in Reference Example 87.
• the above components are blended, granulated and made into 1,000 tablets each weighing 100 mg by a conventional method.
• the above components are blended, granulated and filled into 1,000 capsules by a conventional method.
• the above components are blended and made into fine granules by a conventional method.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Pyridine Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (2)

Family

ID=26442419

Family Applications (1)

Country Status (18)

Cited By (3)

Families Citing this family (33)

Family Cites Families (7)

• 1987
  • 1987-04-24 US US07/042,474 patent/US4870074A/en not_active Expired - Lifetime
  • 1987-04-24 SK SK2897-87A patent/SK279058B6/sk unknown
  • 1987-04-24 CZ CS872897A patent/CZ284687B6/cs not_active IP Right Cessation
  • 1987-04-27 FI FI871828A patent/FI87776C/fi not_active IP Right Cessation
  • 1987-04-28 CA CA000535794A patent/CA1291135C/en not_active Expired - Lifetime
  • 1987-04-28 NZ NZ220120A patent/NZ220120A/xx unknown
  • 1987-04-29 DK DK198702187A patent/DK175281B1/da not_active IP Right Cessation
  • 1987-04-29 EP EP87106266A patent/EP0243959B1/en not_active Expired - Lifetime
  • 1987-04-29 SU SU874202484A patent/SU1597101A3/ru active
  • 1987-04-29 DE DE8787106266T patent/DE3781195T2/de not_active Expired - Lifetime
  • 1987-04-29 ES ES87106266T patent/ES2043617T3/es not_active Expired - Lifetime
  • 1987-04-29 HU HU871946A patent/HU198193B/hu unknown
  • 1987-04-29 PH PH35203A patent/PH24049A/en unknown
  • 1987-04-30 AU AU72275/87A patent/AU592177B2/en not_active Expired
  • 1987-04-30 AR AR87307449A patent/AR242953A1/es active
  • 1987-04-30 KR KR870004220A patent/KR870010030A/ko not_active Application Discontinuation
• 1992
  • 1992-10-12 GR GR920402254T patent/GR3005934T3/el unknown
• 1994
  • 1994-03-03 HK HK181/94A patent/HK18194A/xx not_active IP Right Cessation

Also Published As

Similar Documents

Legal Events